Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02758717 · ClinicalTrials.gov registry record · Phase 2
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma
A Phase 2 study of Ann Arbor Stage IIB Hodgkin Lymphoma and Ann Arbor Stage IB Hodgkin Lymphoma, sponsored by Academic and Community Cancer Research United.
- Active
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 9
- Study locations
NCT02758717 is a Phase 2 study of Ann Arbor Stage IIB Hodgkin Lymphoma and Ann Arbor Stage IB Hodgkin Lymphoma that is active but no longer recruiting, run by Academic and Community Cancer Research United. The registered enrollment target is 46 participants, below the 279-participant average among 3 other Ann Arbor Stage IIB Hodgkin Lymphoma trials with a reported enrollment target (84% lower). The trial reports 9 study locations across 9 states.
The verdict
NCT02758717, a Phase 2 study of Ann Arbor Stage IIB Hodgkin Lymphoma and Ann Arbor Stage IB Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Academic and Community Cancer Research United.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 9
- Study locations
Study Summary
This phase II trial studies how well nivolumab and brentuximab vedotin work in treating older patients with untreated Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Biological therapies, such as brentuximab vedotin, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Nivolumab and brentuximab vedotin may work better in treating older patients with untreated Hodgkin lymphoma.
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
- DRUG Brentuximab Vedotin
Study Locations (9)
California
- Stanford Cancer Institute Palo Alto - Palo Alto
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University School of Medicine - St Louis
New Jersey
- Hackensack University Medical Center - Hackensack
New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone - New York
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2016-05-13 |
| Est. Completion | 2025-09-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02758717
The ClinicalTrials.gov registry entry for NCT02758717 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 279-participant average among 3 other Ann Arbor Stage IIB Hodgkin Lymphoma trials with a reported enrollment target (84% lower). The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Ann Arbor Stage IIB Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT02758717 reports 9 study locations spanning 9 distinct geographic areas - top geographies include California, District of Columbia, Georgia.
Frequently Asked Questions
What is clinical trial NCT02758717 about?
NCT02758717 is a clinical study titled "Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma". This phase II trial studies how well nivolumab and brentuximab vedotin work in treating older patients with untreated Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells ...
What is the current status of trial NCT02758717?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2016-05-13. Estimated completion is 2025-09-13.
What conditions does trial NCT02758717 study?
This clinical trial studies the following conditions: Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage III Hodgkin Lymphoma.
What interventions are being tested in trial NCT02758717?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Brentuximab Vedotin (DRUG).
Who is sponsoring clinical trial NCT02758717?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02758717 being conducted?
This trial has 9 study locations across California, District of Columbia, Georgia, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ann Arbor Stage IIB Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Ann Arbor Stage IIB Hodgkin Lymphoma
All registered trials for this condition
Ann Arbor Stage IB Hodgkin Lymphoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.